User:Ca2001/sandbox

Wikipedia bio

Andrew Robert Marks, MD (born February 22, 1955) is an American cardiologist and molecular biologist. He is Professor and Chair of the Department of Physiology and Cellular Biophysics [1] at Columbia University College of Physicians and Surgeons; Founding Director of the Clyde and Helen Wu Center for Molecular Cardiology [2]; and Wu Professor of Medicine.

Contents •	1 Biography •	2 Awards and Honors •	3 Selected Publications •	4 References •	5 External links

Biography Dr. Marks grew up in New York and attended Amherst College [3] and Harvard Medical School, where he received an MD in 1980. Following an internship and residency in internal medicine at the Massachusetts General Hospital (MGH), he was a post-doctoral fellow in molecular genetics at Harvard Medical School and then a clinical cardiology fellow at the MGH. In 1997 he was recruited to Columbia University College of Physicians & Surgeons.

Andrew Marks identified the mechanism by which the drug rapamycin inhibits vascular smooth muscle proliferation and migration [4]. This discovery was the basis for the development of the first drug-eluting stent (coated with rapamycin) approved for patient use in 2003 for treatment of coronary artery disease, substantially reducing the incidence of in-stent restenosis. He showed how intracellular calcium regualtes fundamental cellular processes, including cardiac and skeletal muscle contraction, lymphocyte activation, cognitive function, and glucose metabolism [5]. He discovered that “leaky” intracellular calcium release channels contribute to heart failure, fatal cardiac arrhythmias, impaired exercise capacity (e.g., muscular dystrophy), post-traumatic stress disorder (PTSD), Alzheimer’s disease and diabetes and discovered and developed in his laboratory a new class of small molecules (Rycals®) that target leaky ryanodine receptor channels and in pre-clinical studies effectively treat cardiac arrhythmias, heart failure, muscular dystrophy and prevent stress-induced cognitive dysfunction. Rycals® are being tested for the treatment of heart failure, cardiac arrhythmias and Duchenne Muscular Dystrophy.

From 2002-2007 Dr. Marks served as Editor-in-Chief of the Journal of Clinical Investigation. Dr. Marks is chair of the SAB of ARMGO Pharma, Inc., [6] a company he founded in 2006 to develop novel therapeutics for heart, muscle and CNS diseases, and he is the inventor on twenty-three U.S. patents. In 2001 Dr. Marks founded the Summer Program for Under-Represented Students (SPURS) at Columbia [7]. SPURS provides mentored research training at Columbia University for minority students from the New York City public colleges and universities. In 2002 Dr. Marks founded IAFI (International Academic Friends of Israel) [8], a not-for-profit organization devoted to promoting and supporting academic freedom. His underwater pictures can be seen at http://yourshot.nationalgeographic.com/profile/1073459/

Awards and Honors 1995	American Society of Clinical Investigation (ASCI) 1999	Association of American Physicians (AAP) 2002-2007	Editor-in-Chief - The Journal of Clinical Investigation

2004	Member, Institute of Medicine, National Academy of Sciences 2005	Fellow, American Academy of Arts and Sciences 2005	Member, National Academy of Sciences, USA

2005	AHA, Basic Research Prize 2009	Doctor of Science, Honoris causa, Amherst College

2010	Stanley J. Korsmeyer Award, ASCI

2011	Robert J. and Claire Pasarow Award in Cardiovascular Disease Research 2011 		    Ellison Medical Foundation Senior Scholar in Aging 2015 		     Ulf von Euler lecturer Karolinska Institute

Selected Publications Brillantes AB, Ondrias K, Scott A, Kobrinsky E, Ondriasova E, Moschella MC, Jayaraman T, Landers M, Ehrlich BE, Marks AR. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell. 1994 May 20;77(4):513-23. Jayaraman T, Ondrias K, Ondriasova E, Marks AR. Regulation of the inositol 1,4,5-trisphosphate receptor by tyrosine phosphorylation. Science. 1996 Jun 7;272(5267):1492-4. Marx SO, Ondrias K, Marks AR. Coupled gating between individual skeletal muscle Ca2+ release channels (ryanodine receptors) Science. 1998 Aug 7;281(5378):818-21. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, Marks AR. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000 May 12;101(4):365-76. Marx SO, Kurokawa J, Reiken S, Motoike H, D'Armiento J, Marks AR, Kass RS. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science. 2002 Jan 18;295(5554):496-9. Wehrens XH, Lehnart SE, Huang F, Vest JA, Reiken SR, Mohler PJ, Sun J, Guatimosim S, Song LS, Rosemblit N, D'Armiento JM, Napolitano C, Memmi M, Priori SG, Lederer WJ, Marks AR. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell. 2003 Jun 27;113(7):829-40. Wehrens XH, Lehnart SE, Reiken SR, Deng SX, Vest JA, Cervantes D, Coromilas J, Landry DW, Marks AR. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science. 2004 Apr 9;304(5668):292-6. Lehnart, S., Wehrens, X., Reiken, S., Warrier, S., Belevych, AE, Harvey, RD, Richter, W., Jin, S.- L. C., Conti, M., and Marks, AR. Phosphodiesterase 4D deficiency in the ryanodine receptor complex promotes heart failure and arrhythmias. Cell. 2005 Oct. 7; 123:25-35 Bellinger, AM, Reiken, SR, Dura, M, Murphy, P, Deng, S-X, Neiman, D, Lehnart, S, Samaru, M, Lacampagne, A, and Marks, AR (2008) Remodeling of ryanodine receptor complex causes "leaky" channels: a molecular mechanism for decreased exercise capacity PNAS 105: 2198-2202 Bellinger, AM, Reiken, S, Carlson, C, Mongillo, M, Liu, X, Rothman, L, Matecki, S, LaCampagne, A, and Marks, AR (2009) Hypernitrosylated ryanodine receptor/calcium release channels are leaky in dystrophic muscle. Nature Medicine 15:325-330 Shan, J., Kushnir, A., Betzenhauser, M., Reiken, S., Li, J., Lehnart, S.E., Lindegger, N., Mongillo, M., Mohler, P.J., Marks, A.R. (2010) Phosphorylation of the Ryanodine Receptor Mediates the Cardiac Fight or Flight Response in Mice J. Clin. Invest. 120: 4375-87. Shan, J., Betzenhauser, M., Kushnir, A., Reiken, S., Meli, A., Wronska, A., Dura, M., Chen, B.-X., Marks, A.R. (2010) Role of Chronic Ryanodine Receptor Phosphorylation in Heart Failure and Beta-adrenergic Receptor Blockade in Mice J. Clin. Invest. 120: 4388-98. Andersson DC, Betzenhauser MJ, Reiken S, Meli AC, Umanskaya A, Xie W, Shiomi T, Zalk R, Lacampagne A, Marks AR. Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 2011 Aug 3;14(2):196-207. Liu, X., Betzenhauser, M.J., Reiken, S., Meli, A.C., Arancio, O., Chen B.-X., Marks AR (2012) Role of Leaky Neuronal Ryanodine Receptors in Stress-Induced Cognitive Dysfunction Cell 150, 1055–1067. Ran Zalk, Oliver B. Clarke, Amédée des Georges, Robert A. Grassucci, Steven Reiken, Filippo Mancia, Wayne A. Hendrickson, Joachim Frank, Marks, A.R. (2014) Structure of a mammalian ryanodine receptor Nature 2014 Dec 1. doi: 10.1038/nature13950. [Epub ahead of print]

References [1] Department of Physiology [2] Wu Center for Molecular Cardiology [3] Doctor of Science, Honoris causa, Amherst College [4] Development of the Drug Eluting Stent [5] “Time line of Andrew R. Marks’ discovery of leaky ryanodine receptors (RyRs) and novel therapeutics that fix this leak” http://www.markslab.columbia.edu/timeline.php.html [6] ARMGO Pharma, Inc. [7] (SPURS) [8] http://www.iafi-israel.org/

External links

Marks lab web site http://www.markslab.columbia.edu/index.php.html